Aktienanalyse zu ANI Pharmaceuticals, Inc. (ANIP)ANIPANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, ANI Pharmaceuticals Inc is trading at $72.29, which is below the average analyst price target of $98.75 (from Oppenheimer, Leerink, and Guggenheim). The forward P/E ratio of 7.12 indicates that the stock may be undervalued compared to its earnings potential. However, the stock has seen a significant decline of 24% over the past year, and insider selling has increased dramatically by 14497.26%, which raises concerns about future performance. Therefore, while the stock shows potential for recovery, the risks associated with insider selling and recent performance suggest a hold rather than a buy at this time.

3 analysts cover ANIP: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 115.00.